Type of Spiritual Experience
A description of the experience
Sunitinib (marketed as Sutent and previously known as SU11248) is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) on January 26, 2006. Sunitinib was the first cancer drug simultaneously approved for two different indications
The most common adverse events associated with sunitinib therapy are fatigue, diarrhea, nausea, anorexia, hypertension, a yellow skin discoloration, hand-foot skin reaction, and stomatitis In the placebo-controlled Phase III GIST study, adverse events which occurred more often with sunitinib than placebo included diarrhea, anorexia, skin discoloration, mucositis/stomatitis, asthenia, altered taste, and constipation
On Feb, 8, 2016: 6,800 people reported to have side effects when taking Sunitinib malate. Among them, 6 people (0.09%) have Hallucination.
On Jan, 31, 2016: 6,800 people reported to have side effects when taking Sunitinib malate. Among them, 418 people (6.15%) have Death.